CODAGENIX
Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchers to invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well.
CODAGENIX
Industry:
Biotechnology Genetics
Founded:
2011-08-01
Address:
Farmingdale, New York, United States
Country:
United States
Website Url:
http://www.codagenix.com
Total Employee:
1+
Status:
Active
Contact:
5168290353
Email Addresses:
[email protected]
Total Funding:
34.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Codagenix
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - Codagenix
Euclidean Capital
Euclidean Capital investment in Series B - Codagenix
Adjuvant Capital
Adjuvant Capital investment in Series B - Codagenix
Topspin Partners
Topspin Partners investment in Series B - Codagenix
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Codagenix
Topspin Partners
Topspin Partners investment in Venture Round - Codagenix
Topspin Partners
Topspin Partners investment in Series A - Codagenix
Accelerate Long Island
Accelerate Long Island investment in Grant - Codagenix
Topspin Partners
Topspin Partners investment in Grant - Codagenix
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-12 | Codagenix Welcomes Bruce Taillon as Executive Vice President of Animal Health |
| 2021-08-26 | Codagenix Appoints Tyler Cook as Chief Financial Officer |
| 2020-10-28 | Codagenix, Inc. Appoints Jeffrey Fu, Ph.D., Chief Business Officer |
Official Site Inspections
http://www.codagenix.com Semrush global rank: 5.11 M Semrush visits lastest month: 1.59 K
- Host name: 104.21.94.82
- IP address: 104.21.94.82
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Codagenix"
Codagenix - Crunchbase Company Profile & Funding
Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering …See details»
Team. Building the viralplatform of the future. | Codagenix
The Codagenix team and its founders pioneered the use of codon deoptimization to construct groundbreaking vaccines and virotheraputics. We are now pushing this proven method into the …See details»
Codagenix Company Profile 2024: Valuation, Funding & Investors
Codagenix General Information Description. Developer of live-attenuated viral vaccine design technology designed to provide target antigens placed in an attenuated backbone virus. The …See details»
Codagenix Inc. - LinkedIn
Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development.See details»
Codagenix Company Profile - Office Locations, Competitors ... - Craft
Codagenix has 5 employees across 2 locations and $49 m in total funding,. See insights on Codagenix including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Codagenix, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Grint said there is a $6 billion market for COVID-19 vaccines, and Codagenix secured a potential $389 million deal with BARDA in October of last year as well as working …See details»
Codagenix - Funding, Financials, Valuation & Investors - Crunchbase
Codagenix is funded by 9 investors. U.S. Department of Defense and Serum Institute of India Pvt. Ltd. are the most recent investors. Codagenix has a post-money valuation in the range of …See details»
Codagenix - Contacts, Employees, Board Members, Advisors
Organization. Codagenix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of Board …See details»
Approach. Precision is power. - Codagenix
Codagenix is pushing this proven approach into the clinic and beyond by merging live-attenuated viruses with a novel codon deoptimization approach that leverages cutting-edge developments …See details»
Codagenix Announces Close of $25 million Extension of Series B
Feb 15, 2023 Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is …See details»
Codagenix Announces BARDA Contract for Project NextGen …
Oct 3, 2023 Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is …See details»
Codagenix Announces BARDA Contract for Project NextGen …
Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. The company’s breakthrough platform brings together live-attenuated virus …See details»
Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal ...
Oct 26, 2022 Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is …See details»
Codagenix Receives FDA Clearance of Investigational New Drug ...
Jun 1, 2022 Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. The company's breakthrough platform brings together live …See details»
Codagenix begins Phase 3 Clinical Testing of its COVID-19 Vaccine ...
Farmingdale, N.Y., October 26, 2022 – Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, in …See details»
Codagenix Intranasal COVID-19 Vaccine Shows Potent Cellular …
CoviLiv is a participant in a World Health Organization (WHO) global, placebo-controlled Phase 2/3 efficacy trial for COVID-19 (WHO-sponsored, Solidarity Trial Vaccines), with dosing …See details»
Codagenix Announces Late-Breaking Presentation of Positive …
Oct 11, 2023 Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is …See details»
Pipeline. Faster, better viralvaccines and therapeutics ... - Codagenix
Codagenix has leveraged our platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. Zika. …See details»
Codagenix Intranasal COVID-19 Vaccine Shows Potent Cellular …
Mar 17, 2022 Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is …See details»